

## Meda AB

[View the current Meda AB Page on BioPortfolio.com](http://www.bioportfolio.com/biocorporate/26154-Meda+AB.html)

(<http://www.bioportfolio.com/biocorporate/26154-Meda+AB.html>)

### Contact Details:

Box 906

Solna

SE-170 09

Sweden

Tel: 46 8-630 19 00

Fax: 46 8-630 19 50

Email: [info@meda.se](mailto:info@meda.se)

Meda is one of Europe's leading specialty pharma companies. Meda covers all of Europe via its subsidiaries in more than 20 European countries; it has 900 employees in marketing and sales. In other world markets, agents and other pharma companies market and sell Meda's pharmaceuticals. Specialisation occurs within marketing and market-adapted product development. A key part of its product flow is also created through partnerships, in-licensing, and product acquisitions. Meda's pan-European marketing organisation and its capacity for product registration and development, make the company an attractive partner for pharmaceutical out-licensors.

### Press Releases on Meda AB:

#### [Meda Launches](#)

[Onsolis\(TM\) \(Fentanyl Buccal Soluble Film\) for the Treatment of Breakthrough Cancer Pain in Opioid Tolerant Patients](#)

13th October, 2009

Meda Pharmaceuticals Inc.

-- Training prescribers, pharmacists, and patients about proper dosing and administration. Under the FOCUS Program, only prescribers, pharmacies, and patients registered with the ALISO VIEJO, Calif., Jan. 13 /PRNewswire-FirstCall/ --  
Valeant Pharmaceuticals International (NYSE: VRX) today announced the appointment of Anders Lonner to its Board of Directors. Mr. Lonner was

[Valeant Pharmaceuticals Appoints Anders Lonner of Meda to Fill Board Vacancy](#)

13th January, 2009

Valeant Pharmaceuticals International

[ULURU Inc. Announces Signing of European Agreement With Meda AB for the Marketing of Amlexanox 5 Percent Paste and OraDisc\(TM\) A](#) 17th November, 2008 ULURU Inc.

ADDISON, Texas, Nov. 17 /PRNewswire-FirstCall/ -- ULURU Inc. (NYSE Alternext: ULU) today announced the signing of a License Agreement with Meda AB (Meda) to market Amlexanox 5% paste and OraDisc(TM) A

[Innocoll Appoints Anthony H. Wild Ph.D. to Its Board of Directors](#) 21st July, 2008 Innocoll Inc.

ASHBURN, Va., July 21 /PRNewswire/ -- Innocoll Inc. today announced that Anthony H. Wild, Ph.D. has been appointed to its board of directors. Dr. Wild is a co-founder and General Partner of

## BioNews Results for Meda AB



- [MSU team looks for characteristics of virtual workout partners to help improve physical fitness](#)  
*News-Medical.Net: Nov 13 2009 1:51PM Matching: meda ab*
- [Orexo AB \(publ\) ?? Interim report January-September 2009](#)  
*Therapeutics Daily: Nov 10 2009 12:33PM Matching: meda ab*
- [Orexo AB \(publ\) Interim report January-September 2009](#)  
*Pharmacy Choice: Nov 10 2009 10:53PM Matching: meda ab*
- [Meda AB \(publ\) - Interim report, January -September 2009](#)  
*SmartBrief: Nov 3 2009 10:52AM Matching: meda ab*
- [FDA approves Raleigh-based BioDelivery Sciences powerful painkiller](#)  
*Local Tech Wire: Oct 30 2009 3:32PM Matching: meda ab*
- [BioDelivery Sciences Announces New Drug Submission in Canada for BEMA Fentanyl](#)  
*Pharma Live: Oct 7 2009 1:37PM Matching: meda ab*
- [Meda: Onsolis Filed in Canada](#)  
*Pharma Live: Oct 7 2009 1:38PM Matching: meda ab*
- [Meda, Cipla Extend Collaboration For Azelastine, Fluticasone Combination](#)  
*Pharmaceutical Business Review: Sep 8 2009 10:51AM Matching: meda ab*
- [Meda Wins FDA Approval For Astepro](#)  
*Pharmaceutical Business Review: Sep 3 2009 10:37PM Matching: meda ab*
- [Meda: FDA Approval of the First Once-Daily Nasal Antihistamine](#)  
*Pharma Live: Sep 2 2009 1:06PM Matching: meda ab*
- [BioDelivery Sciences Announces Issuance of U.S. Patent Extending Exclusivity for the BEMA Delivery Technology](#)  
*Pharma Live: Aug 25 2009 7:58PM Matching: meda ab*

## BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

\*\*\*

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

